Search results
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 21 hours agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report ...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 5 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga via Yahoo Finance· 4 days agoOn Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8...
Merck Lifts FY24 Outlook After Higher Q1 Earnings, Above Market; Stock Up In Pre-market
RTT News· 5 days agoDrug major Merck & Co., Inc. (MRK), while reporting higher first-quarter earnings, above market estimates, on Thursday raised its fiscal 2024 adjusted earnings and sales view.
Merck Earnings Preview: Strong quarter expectations on the back of core products' growth
Seeking Alpha· 6 days agoMerck (NYSE:MRK) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market...
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in...
FOX 23 News Albany· 6 days agoUpon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to...
S&P 500 Down Over 1%; Merck Increases 2024 Outlook - ATN International (NASDAQ:ATNI), Hertz Global...
Benzinga· 5 days agoATNI shares dropped 30% to $20.12 as the company posted weak quarterly sales...Forecasts For...
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Benzinga via Yahoo Finance· 5 days agoThe investigational immuno...
Dow Jones fumbles after US GDP flubs expectations but inflation still hot
The Forex Market· 4 days agoDow Jones backslides over 500 points as investors balk at inflation complications. US GDP eased...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 hours ago- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism Data of BeyondSpring’s Lead Asset Plinabulin
